Anti-PD1 therapy with nivolumab in sarcoma.

Abstract

11047Background: Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and bone sarcomas have been shown to express PD-1 ligand. Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies, has recently emerged as an effective anticancer strategy in multiple malignancies. Methods: We retrospectively analyzed a cohort of patients (pts) with relapsed metastatic sarcomas, who were treated with nivolumab provided under a patient assistance program from the manufacturer. Pts underwent CT or PET/CT imaging at baseline and after at least 6 doses of nivolumab; RECIST criteria were used for response assessment. Results: Twenty-three pretreated pts with metastatic soft tissue (STS, N = 20) or bone sarcoma (N = 3), received IV nivolumab 3mg/kg every 2 weeks from July 2015 to January 2016. Median age was 58 (24-78), male:female was 10:13; ECOG PS was 0-1 in 19 pts, 2 in 4 pts; the median number of previous treatments was two (0-5);...